Gilead HCV Sales Decline In US, But Offset By Global Growth
This article was originally published in Scrip
Executive Summary
Strong sales growth continues almost unabated at Gilead Sciences Inc., but the virology powerhouse reported that domestic sales for its hepatitis C drugs actually decreased by 26% year-over-year during the fourth quarter.
You may also be interested in...
Gilead Not Bullet-Proof After All: Harvoni US Sales Tumble More Than 50%
Incoming President and CEO John Milligan opened Gilead Sciences Inc.'s first quarter earnings call April 28 talking about sales growth of new HIV drugs and pipeline efforts in non-alcoholic steatohepatitis (NASH), but analysts focused in quickly on overall reductions in hepatitis C sales, including a more than 50% decrease year-over-year in US sales of Harvoni.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.